

Chapter 23: Tuberculosis



NATIONAL DEPARTMENT OF HEALTH



AFFORDABLE MEDICINES DIRECTORATE
ESSENTIAL DRUGS PROGRAMME



PRIMARY HEALTHCARE STANDARD TREATMENT
GUIDELINES AND ESSENTIAL MEDICINES LIST
2025-2029 REVIEW CYCLE



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



How to Use this Implementation Tool



This slide set highlights medicine amendments to this chapter of the PHC STGs & EML



THIS TOOL

- ✓ Highlights medicine amendments
- ✓ Use for quick implementation updates



STGs

- ✓ Remains the authoritative clinical guidance
- ✓ Always use the most recently published version



EVIDENCE

- ✓ Access the NEMLC report for detailed evidence (including rationale, references and costings) informing decision-making on medicine addition, amendments and deletions

**ACCESS THE LATEST
STGs & EML**
PHC Chapter 23: Tuberculosis



NHI webpage:
<https://www.health.gov.za/nhi-edp-stgs-eml/>



Disclaimer

This slide set is an implementation tool and should be used alongside the most recently published STG available on the NHI Webpage as detailed above. This information does not supersede or replace the STG itself.



health

Department:
Health
REPUBLIC OF SOUTH AFRICA




Why a new chapter for Tuberculosis



Consolidates Guidance

TB content previously spread across multiple PHC Chapters is now consolidated in a single comprehensive chapter (Chapter 23).




Aligns with National Programme Guidelines

Updates broadly align with the National TB Programme Guidelines and evidence.



Improves Continuity of Care

Provides a complete user-friendly resource for drug-susceptible and drug resistant TB-for all age groups.



Supports Implementation

Strengthens consistent implementation across facilities.



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Chapter 23 Overview



23.1 Drug-susceptible TB

- Perinatal TB
- Children and adolescents (<15 years old)
- Adults and adolescents (≥15 years old)



23.2 Drug-resistant TB

- Isoniazid monoresistant TB
- Rifampicin-resistant, pre-XDR and XDR-TB



23.3 TB Preventative Therapy (TPT) in eligible children and CALHIV

- Drug-susceptible TB exposure
- Drug-resistant TB exposure



Includes guidance for Adults, Adolescents and Children



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Changes in this Chapter



4

**NEW
STG/SECTIONS**



19

**MEDICINE
ADDITIONS**



6

AMMENDMENTS

Newly developed STGs added to the PHC publication include:

STG/SECTION	GUIDANCE PRODUCTS (Tick relevant)			
	PHC STGs & EML	AH STG & EML	PaedH STG & EML	TQ EML
Report Version 1.0				
23.1 Drug-susceptible tuberculosis	√	√		
23.1.1 Perinatal tuberculosis	√			
23.2.1.2 Isoniazid monoresistant tuberculosis in Children <15 year	√			
23.3 Tuberculosis preventive therapy	√			



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Key Medicine Changes to remember



01



Ethambutol

Added to paediatric drug-susceptible TB regimen

04



Drug-resistant TB medicines

Medicines incorporated

02



Rifampicin/isoniazid co-formulations

60/60mg removed from EML and replaced with dispersible formulations

05



3RH TPT

Use expanded to HIV-negative children or HIV-exposed children not on nevirapine and weighing < 25 kg

03



Pyridoxine

Indication updated

06



Levofloxacin and rifampicin TPT

DR-TB TPT guidance amended for children ≤ 5 years and CALHIV



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments



SECTION 23.1.2: Drug-Susceptible Tuberculosis in Children and Adolescents (<15 years)

Medicine/ Management	Decision	
Definition of a significant TB exposure	 ADDED	Refer to NEMLC report for definition
Treatment Course Duration	 AMENDED	For non-severe TB, the course of therapy was amended from a 4-month continuation phase to a 2-month continuation phase.
Ethambutol	 ADDED	Added as 4 th Drug for children ≤8 years old
Rifampicin/isoniazid, 60/60mg formulation dosing table	 DELETED	Removed and replaced with dispersible RH75/50 and RHZ 75/50/150 formulations
Pyridoxine	 AMENDED	Pyridoxine indications aligned with the National TB Guidelines for Children and Adolescents
Common Adverse Drug Reactions	 ADDED	Common adverse effects table added with cross-reference to appropriate management guidance.



Medicine Amendments



SECTION 23.1.3: Drug-susceptible Tuberculosis in Adults and Adolescents (≥ 15 years)

Medicine/ Management

STG Update

STG guidance on the management of DS-TB in adults and adolescents (≥ 15 years) has been amended, with the addition of monitoring guidance.



Refer to [NEMLC report](#) for the table showing amendments



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments




SECTION 23.2: Drug-resistant Tuberculosis (DR-TB)

Medicine/ Management

Decision

STG Update

STG guidance on the management of drug-resistant TB has been amended



Refer to [NEMLC report](#) for the table showing amendments



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments



SECTION 23.2.1.1: Isoniazid monoresistant Tuberculosis in Adults

Medicine/ Management

Decision

STG Update

STG guidance on the management of isoniazid monoresistant TB in adults has been amended



Refer to [NEMLC report](#) for the table showing amendments



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments



New STG Added



SECTION 23.2.1.2: Isoniazid monoresistant Tuberculosis in Children < 15 years

Medicine/ Management

Decision

Confirmed isoniazid monoresistant TB

Rifampicin/isoniazid/pyrazinamide/ethambutol



Levofloxacin



Pyridoxine



Confirmed isoniazid monoresistant TB and contraindication to isoniazid

Rifampicin



Ethambutol



Pyrazinamide



Levofloxacin



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments




SECTION 23.2.2.2: Rifampicin-resistant, pre-XDR and XDR Tuberculosis in adults and adolescents ≥ 15 years

Medicine/ Management	Decision
Bedaquiline Rifampicin-resistant, pre-XDR in adults and adolescents ≥ 15 years (6-month BPaL-L regimen)	
Linezolid Rifampicin-resistant, pre-XDR and XDR tuberculosis in adults and adolescents ≥ 15 years (6-month BPaL-L regimen)	
Levofloxacin Rifampicin-resistant, tuberculosis in adults and adolescents ≥ 15 years (6-month BPaL-L regimen)	
Pretomanid Rifampicin-resistant, pre-XDR in adults and adolescents ≥ 15 years (6-month BPaL-L regimen)	
Clofazimine Rifampicin-resistant, pre-XDR and XDR tuberculosis in adults and adolescents ≥ 15 years (individualised regimens)	
Terizidone Rifampicin-resistant, pre-XDR and XDR tuberculosis in adults and adolescents ≥ 15 years (individualised regimens)	

Medicine Amendments



SECTION 23.2.2.2: Rifampicin Resistant, pre-XDR and XDR Tuberculosis in adults and adolescents ≥ 15 years

Medicine/ Management	Decision
Delamanid Rifampicin-resistant, pre-XDR and XDR tuberculosis in adults and adolescents ≥ 15 years (individualised regimens)	
Ethambutol Rifampicin-resistant, pre-XDR and XDR tuberculosis in adults and adolescents ≥ 15 years (individualised regimens)	
Pyrazinamide Rifampicin-resistant, pre-XDR and XDR tuberculosis in adults and adolescents ≥ 15 years (individualised regimens)	
Ethionamide Rifampicin-resistant, pre-XDR and XDR tuberculosis in adults and adolescents ≥ 15 years (individualised regimens)	
Para-amino salicylic Acid Rifampicin-resistant, pre-XDR and XDR tuberculosis in adults and adolescents ≥ 15 years (individualised regimens)	



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments



SECTION 23.2.2.2: Rifampicin-resistant, pre-XDR and XDR Tuberculosis in adults and adolescents ≥ 15 years

Medicine/ Management

Decision

STG Update

STG guidance on the management of rifampicin-resistant, pre-XDR and XDR-TB in adults and adolescents ≥ 15 years has been amended



Refer to [NEMLC report](#) for the table showing amendments



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments



SECTION 23.2.3: Rifampicin-resistant (RR), pre-XDR and XDR tuberculosis in children and adolescents < 15 years

Medicine/ Management	Decision
Bedaquiline	 ADDED
Clofazimine	 ADDED
Delamanid	 ADDED
Ethionamide	 ADDED
High-dose isoniazid	 ADDED
Levofloxacin	 ADDED
Linezolid	 ADDED
Para-amino salicylic Acid	 ADDED
Terizidone	 ADDED



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments




SECTION 23.2.3: Rifampicin-resistant (RR), pre-XDR and XDR tuberculosis in children and adolescents < 15 years

Medicine/ Management

Decision

STG Update

STG guidance on the management of rifampicin-resistant, pre-XDR and XDR TB in children has been updated.



Refer to [NEMLC report](#) for the table showing amendments



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments



SECTION 23.3.1: Tuberculosis preventive therapy (TPT) for drug-susceptible tuberculosis exposure

Medicine/ Management

Decision

3RH

Rifampicin/isoniazid 75/50 mg daily for 3 months (3RH)



For HIV-negative children and HIV-exposed children not on nevirapine, who are ≤ 5 years and < 25 kg with a significant TB exposure after excluding TB disease.
(previously only included for perinatal TPT)



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Medicine Amendments



SECTION 23.3.2: Tuberculosis preventative therapy (TPT) for drug-resistant tuberculosis exposure

Medicine/ Management

Decision

STG Update

Guidance on TB preventive therapy for children ≤ 5 years and CALHIV with significant DR-TB exposure has been updated.



Refer to [NEMLC report](#) for further information

Isoniazid monoresistance (rifampicin-susceptible)

Rifampicin dosing table



Refer to [NEMLC report](#) for the dosing table

Rifampicin-resistant fluoroquinolone-susceptible)

Levofloxacin



Refer to [NEMLC report](#) for further information



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Additional Considerations



Aligned with National Guidelines

- Management of Tuberculosis in Children and Adolescents – A Clinical Guideline for diagnosis and treatment of Drug-susceptible TB in Children and Adolescents in South Africa, September 2024.
- Management of Tuberculosis in Children and Adolescents (0-15 years) – A quick Reference Guide.
- Clinical Management of Rifampicin-Resistant Tuberculosis – Updated Clinical Reference Guide, September 2023.
- National Department of Health. Updated Clinical Reference Guide: Clinical Management of Rifampicin Resistant Tuberculosis. September 2023.



Age thresholds aligned with national guidelines and for pragmatic reasons

STGs have aligned as follows:

- Drug-susceptible TB: Children < 15 years potentially eligible for treatment shortening.
- Drug-resistant TB: Children ≥ 15 years eligible for BPaL



Dosing tables updated

Dosing tables were aligned with those in the National Programme TB Guidelines for consistency.



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Refer to [NEMLC report](#) for further information





THANK YOU



For any queries kindly email
SAEDP@health.gov.za



NHI Webpage

<https://www.health.gov.za/nhi-edp-stgs-eml/>



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

